Current thinking in lipid lowering

American Journal of Medicine

Volumn 104, Issue 6 A, 1998, Pages 33S-41S

  Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ATORVASTATIN; BEZAFIBRATE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CERIVASTATIN; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; RESIN; SIMVASTATIN; TRIACYLGLYCEROL;

CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIET RESTRICTION; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION;

EID: 0031855707     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(98)00186-7     Document Type: Review

References (66)

1. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445.
2. Patsch JR, Miesenböck G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12: 1336-1345.
3. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med. 1995;332:1491-1498.
4. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
5. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol. 1988;4(suppl A):5A-10A.
6. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
7. Superko HR. Beyond LDL cholesterol reduction. (Editorial.) Circulation. 1996;94:2351-2354.
8. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis. 1990;10:672-679.
9. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996;276: 544-548.
10. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
11. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
12. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications: a statement for health professionals from the American Heart Association. Circulation. 1996;94:1175-1192.
13. Ernst E. Plasma fibrinogen - an independent cardiovascular risk factor. J Intern Med. 1990;227:365-372.
14. Hwang S-J, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96:4219-4225.
15. Ballantyne CM, Abe Y. Molecular markers for atherosclerosis. J Cardiovasc Risk. 1997;4:353-356.
16. Marian AJ. Genetic markers: genes involved in atherosclerosis. J Cardiovasc Risk. 1997;4:333-339.
17. Health Canada guidelines: investigation and treatment of hyperlipidemia. Can J Cardiol. In press.
18. Pyörälä K, De Backer G, Graham I, et al, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
19. International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines: recommendations of the European Atherosclerosis Society. Nutr Metab Cardiovasc Dis. 1992;2:113-156.
20. Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation. 1997;95:1683-1685.
21. Stone NJ, Nicolosi RJ, Kris-Etherton P, et al. Summary of the Scientific Conference on the Efficacy of Hypocholesterolemic Dietary Interventions. Circulation. 1996;94:3388-3391.
22. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336:129-133.
23. Knopp RH, Walden CE, Retzlaff BM, et al. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men: the Dietary Alternatives Study. JAMA. 1997;278:1509-1515.
24. Reaven GM. Do high carbohydrate diets prevent the development or attenuate the manifestations (or both) of syndrome X? A viewpoint strongly against. Curr Opin Lipidol. 1997;8:23-27.
25. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vase Biol. 1995;15: 678-682.
26. Insull W, Stein E, Whalen E, Ripa S, for the Cerivastatin Study Group. Cerivastatin, a new potent HMG-CoA reductase inhibitor: efficacy and tolerability in primary hypercholesterolemia. (Abstr.) J Am Coll Cardiol. 1997;29:46A.
27. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997;79:38-42.
28. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128-133.
29. Ballantyne CM, Herd JA, Schein JR, et al. Insights from the Lipoprotein and Coronary Atherosclerosis Study (LCAS). Cardiovasc Risk Factors. In press.
30. Ballantyne CM, Herd JA, West MS, et al. Influence of low HDL-C on progression of CAD and response to fluvastatin therapy. (Abstr.) J Am Coll Cardiol. 1997;29:232A.
31. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
32. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
33. Tilly-Kiesi M, Tikkanen MJ. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil. J Intern Med. 1991;229:427-434.
34. Eisenberg S, Gavish D, Oschry Y, et al. Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia: reversal toward normal with bezafibrate treatment. J Clin Invest. 1984;74:470-482.
35. Superko HR and KOS investigators. Effect of nicotinic acid on LDL subclass patterns. (Abstr.) Circulation. 1994;90:I-504.
36. Griffin B, Farish E, Walsh D, et al. Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause. Clin Endocrinol. 1993;39:463-468.
37. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.
38. Regnström J, Walldius G, Nilsson S, et al. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis. 1996;125:217-229.
39. Kajinami K, Nishitsuji M, Takeda Y, et al. Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. Atherosclerosis. 1996;120:181-187.
40. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol. 1994;74:875-883.
41. Tardif J-C, Côté G, Lespérance J, et al, for the Multivitamins and Probucol Study Group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1997;337:365-372.
42. Yokoi H, Daida H , Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol. 1997;30:855-862.
43. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.
44. Ericsson C-G, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.
45. Frick MH, Syvänne M, Nieminen MS, et al, for the Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and veingraft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation. 1997;96:2137-2143.
46. Bimmermann A, Boerschmann C, Schwartzkopff W, et al. Effective therapeutic measures for reducing lipoprotein (a) in patients with dyslipidemia. Lipoprotein (a) reduction with sustained-release bezafibrate. Curr Ther Res. 1991;49: 635-643.
47. Branchi A, Rovellini A, Fiorenza AM, Sommariva D. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. Int J Clin Pharmacol Ther. 1995;33:345-350.
48. Kroon AA, van Asten WNJC, Stalenhoef AFH. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med. 1996;125:945-954.
49. Kroon AA, Aengevaeren WRM, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996;93: 1826-1835.
50. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995;76:69C-77C.
51. Jacobson TA. Cost-effectiveness of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol. 1996;78(suppl 6A):32-41.
52. Brown BG, Zhao X-Q, Bardsley J, Albers JJ. Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States. J Intern Med. 1997;241:283-294.
53. Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol. 1994;73(suppl):25D-29D.
54. Gardner SF, Schneider EF, Granberry MC, Carter IR. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy. 1996;16:419-423.
55. Jacobson TA, Chin MM, Fromell GJ, et al. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 1994;74:149-154.
56. Stein EA, Davidson MH, Dujovne CA, et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Therapeut. 1996; 1:107-116.
57. Glueck CJ, Oakes N, Speirs J, et al. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol. 1992;70:1-9.
58. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993;94:13-20.
59. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 1997; 17:1521-1526.
60. Corsini A, Pazzucconi F, Pfister P, et al. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. (Letter.) Lancet. 1996;348:1584.
61. Watts GF, Burke V. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol. 1996,7:341-355.
62. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131.
63. Hackman A, Abe Y, Insull W Jr, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996;93:1334-1338.
64. Gotto AM Jr. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Presented at the American Heart Association 70th Scientific Sessions; November 12, 1997; Orlando, FL.
65. Tonkin A. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID). Presented at the American Heart Association 70th Scientific Sessions; November 12, 1997; Orlando, FL.
66. Goldman L, Garber AM, Grover SA, Hlatky MA. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol. 1996;27:1020-1030.